Thrasos: Thrasos Completes Enrollment Of Phase II THR-184 Clinical Study For Acute Kidney Injury

MONTREAL--(www.businesswire.com/">BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, announced the completion of enrollment in its Phase 2 clinical study of THR-184 for the prevention of acute kidney injury (AKI) in at risk patients undergoing cardiac surgery...